Impaired activation of transposable elements in SARS-CoV-2 infection.


Journal

EMBO reports
ISSN: 1469-3178
Titre abrégé: EMBO Rep
Pays: England
ID NLM: 100963049

Informations de publication

Date de publication:
05 09 2022
Historique:
revised: 26 07 2022
received: 23 03 2022
accepted: 27 07 2022
pubmed: 17 8 2022
medline: 9 9 2022
entrez: 16 8 2022
Statut: ppublish

Résumé

Emerging evidence shows that transposable elements (TEs) are induced in response to viral infections. This TE induction is suggested to trigger a robust and durable interferon response, providing a host defense mechanism. Here, we analyze TE expression changes in response to SARS-CoV-2 infection in different human cellular models. Unlike other viruses, SARS-CoV-2 infection does not lead to global upregulation of TEs in primary cells. We report a correlation between TEs activation and induction of interferon-related genes, suggesting that failure to activate TEs may account for the weak interferon response. Moreover, we identify two variables that explain most of the observed diverseness in immune responses: basal expression levels of TEs in the pre-infected cells and the viral load. Finally, analyzing the SARS-CoV-2 interactome and the epigenetic landscape around the TEs activated following infection, we identify SARS-CoV-2 interacting proteins, which may regulate chromatin structure and TE transcription. This work provides a possible functional explanation for SARS-CoV-2 success in its fight against the host immune system and suggests that TEs could serve as potential drug targets for COVID-19.

Identifiants

pubmed: 35972201
doi: 10.15252/embr.202255101
pmc: PMC9442302
doi:

Substances chimiques

Antiviral Agents 0
DNA Transposable Elements 0
Interferons 9008-11-1

Banques de données

GEO
['GSE133329', 'GSE147507', 'GSE153277', 'GSE153970']

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e55101

Informations de copyright

© 2022 The Authors. Published under the terms of the CC BY NC ND 4.0 license.

Références

J Virol. 2021 May 24;95(12):
pubmed: 33883223
Int J Mol Sci. 2021 Jul 13;22(14):
pubmed: 34299101
Annu Rev Pathol. 2020 Jan 24;15:51-70
pubmed: 31977294
Cell Stem Cell. 2020 Dec 3;27(6):962-973.e7
pubmed: 32979316
Cell. 2013 Apr 25;153(3):590-600
pubmed: 23622243
JCI Insight. 2021 Dec 22;6(24):
pubmed: 34731091
Nat Biotechnol. 2011 Oct 30;29(11):1046-51
pubmed: 22037378
Front Microbiol. 2017 Dec 12;8:2489
pubmed: 29312197
Cell Host Microbe. 2020 Jun 10;27(6):870-878
pubmed: 32464097
J Virol. 2021 Jan 29;:
pubmed: 33514628
Cell. 2015 Aug 27;162(5):961-73
pubmed: 26317465
Cell. 2020 May 28;181(5):1036-1045.e9
pubmed: 32416070
Cell. 2017 Jul 27;170(3):492-506.e14
pubmed: 28753426
EMBO Rep. 2022 Sep 5;23(9):e55101
pubmed: 35972201
Sci Rep. 2022 Feb 9;12(1):2188
pubmed: 35140280
Commun Biol. 2022 Jan 12;5(1):45
pubmed: 35022513
J Biol Chem. 2013 Jul 19;288(29):21148-21160
pubmed: 23754279
EBioMedicine. 2021 Apr;66:103341
pubmed: 33867312
Nat Commun. 2019 Dec 10;10(1):5640
pubmed: 31822674
Curr Opin Virol. 2022 Feb;52:211-216
pubmed: 34959082
Virol Sin. 2021 Dec;36(6):1315-1326
pubmed: 34009516
Mob DNA. 2019 Sep 03;10:39
pubmed: 31497073
Science. 2016 Mar 4;351(6277):1083-7
pubmed: 26941318
Nat Immunol. 2021 Jan;22(1):32-40
pubmed: 33277638
Front Immunol. 2018 Sep 28;9:2229
pubmed: 30323812
NAR Genom Bioinform. 2019 Jul 30;1(1):e3
pubmed: 33575550
Science. 2015 Oct 23;350(6259):455-9
pubmed: 26382853
Front Immunol. 2020 Dec 22;11:586111
pubmed: 33414783
Nat Rev Genet. 2017 Feb;18(2):71-86
pubmed: 27867194
Proc Natl Acad Sci U S A. 2018 Dec 11;115(50):12565-12572
pubmed: 30455304
Sci Immunol. 2022 Jan 07;7(67):eabm5505
pubmed: 34995097
RNA. 2021 Apr 22;:
pubmed: 33888553
Commun Biol. 2021 May 17;4(1):590
pubmed: 34002013
Life Sci Alliance. 2020 Jan 21;3(2):
pubmed: 31964680
Trends Pharmacol Sci. 2020 Aug;41(8):513-517
pubmed: 32553545
Mol Cell. 2022 Feb 17;82(4):816-832.e12
pubmed: 35081363
Nat Rev Endocrinol. 2018 Oct;14(10):576-590
pubmed: 30046148
Microbiol Spectr. 2021 Oct 31;9(2):e0126021
pubmed: 34612698
Nature. 2022 Mar;603(7899):145-151
pubmed: 35045565
Cell. 2015 Aug 27;162(5):974-86
pubmed: 26317466
Proc Natl Acad Sci U S A. 2019 Aug 27;116(35):17399-17408
pubmed: 31391303

Auteurs

Matan Sorek (M)

Department of Genetics, The Institute of Life Sciences, The Hebrew University of Jerusalem, Jerusalem, Israel.
Edmond and Lily Safra Center for Brain Sciences (ELSC), The Hebrew University of Jerusalem, Jerusalem, Israel.
Department of Animal Sciences, Faculty of Agriculture, The Hebrew University of Jerusalem, Rehovot, Israel.

Eran Meshorer (E)

Department of Genetics, The Institute of Life Sciences, The Hebrew University of Jerusalem, Jerusalem, Israel.
Edmond and Lily Safra Center for Brain Sciences (ELSC), The Hebrew University of Jerusalem, Jerusalem, Israel.

Sharon Schlesinger (S)

Department of Animal Sciences, Faculty of Agriculture, The Hebrew University of Jerusalem, Rehovot, Israel.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH